Ophthalmic follow-up of patients with tyrosinaemia type I on NTBC.

Paul Gissen, Mary Preece, HA Willshaw, Patrick McKiernan

Research output: Contribution to journalArticle

36 Citations (Scopus)


NTBC has revolutionized the management of tyrosinaemia type I, although animal experiments have shown that long-term administration may produce corneal opacities analogous to those in tyrosinaemia type II. We have assessed the prevalence of ocular side-effects in 11 tyrosinaemia type I patients on NTBC attending the Birmingham Children's Hospital. Despite high plasma tyrosine concentrations in some patients, they did not experience symptoms or signs of ocular toxicity.
Original languageEnglish
Pages (from-to)13-6
Number of pages4
JournalJournal of Inherited Metabolic Disease
Issue number1
Publication statusPublished - 1 Jan 2003


Dive into the research topics of 'Ophthalmic follow-up of patients with tyrosinaemia type I on NTBC.'. Together they form a unique fingerprint.

Cite this